Table 3

Distribution of PfMDR1 polymorphism according the status drug sensitivity groups
Drug Profils N N° (%), of strains with polymorphism : (Pfmdr)
N86Y D1246Y
N Y MIX p D Y MIX p
CQ Resistant (IC50>100 nM) 20 13 (65.0%) 6 (30.0%) 1 (5.0%) 0.39 14 (70.0%) 2 (10.0%) 4 (20.0%) 0.3
Sensitive (IC50<100 nM) 26 15 (57.7%) 11 (42.3%) 0 (0.0%) 18 (69.2%) 6 (23.1%) 2 (7.7%)
MDAQ Resistant (IC50 ≥ 60 nM) 24 14 (58.3%) 9 (37.5%) 1 (4.2%) 0.28 16 (66.7%) 3 (12.5%) 5 (20.8%) 0.09
Sensitive (IC50 < 60 nM) 22 12 (54.5%) 10 (45.5%) 0 (0.0%) 20 (90.9%) 0 (0.0%) 2 (9.1%)
MF Resistant (IC50>20 nM) 11 6 (54.5%) 5 (45.5%) 0 (0.0%) 0.7 7 (63.6%) 2 (18.2%) 2 (18.2%) 0.23
Sensitive (IC50<20 nM) 35 22 (62.8%) 12 (34.3%) 1 (2,9%) 28 (80.0%) 2 (5.7%) 5 (14.3%)
DHA Reduced susceptibility (IC50 ≥ 10 nM) 11 6 (54.5%) 5 (45.5%) 0 (0.0%) 0.7 9 (81.8%) 1 (9.1%) 1 (9.1%) 0.53
Sensitive (IC50<10 nM) 35 22 (62.8%) 12 (34.3%) 1 (2.9%) 27 (77.1%) 2 (5.7%) 6 (17.1%)

Zatra et al.

Zatra et al. BMC Infectious Diseases 2012 12:307   doi:10.1186/1471-2334-12-307

Open Data